Exogenous administration of purified human serum-derived AAT is the only specific treatment approved for AATD in nonsmoking patients with severe deficiency (serum AAT concentration of < 57 mg/dL or < 11 μM), with evidence of functional loss above the physiological level. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.